> Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of rivastigmi ne with torsades de poi ntes-induc ing medicinal products such as ANTIPSYCHOTICS i.e. some phenot hiazines (CHLORPROMAZINE, LEVOMEPROMAZINE), BENZAMIDES (SULPIRIDE, sultopride, ami sulpride, tiapride, veralipride), PIMOZIDE, ha loperi dol, droperi dol, cisaprid e, CITALOPRAM, diphemanil, ERYTHROMYCIN IV, halofantrin, mizolastin, METHADONE , PENTAMIDINE and moxifl oxacine should be observed with  caution and clinical monito ring (ECG) may also be  required.
> No pharmacokinetic interaction was observed between rivastigmine and DIGOXIN, WARFARIN, DIAZEPAM or FLUOXETINE in studies in healthy volunteers. The inc rease in prothrombin time induced by WARFARIN is 6 not affected by administration of rivastigmine. No untoward effects on cardiac  conduction were observed following concomitant administration of DIGOXIN and rivastigmine. 
